MEDIGEN – MPP AGREEMENT
5. CONFIDENTIALITY AND IP RIGHTS
5.4. IP RIGHTS
i. MEDIGEN will own the entire right, title and interest in and to the Licenced Technology as well as any and all MEDIGEN New Developments, subject only to Clause 9 of Schedule 3 hereto;
ii. If, at any time during the term of this Agreement any Sublicensee (or any of their respective employees, agents, or other persons acting under their authority) makes, develops, conceives, acquires, reduces to practice, becomes entitled to or secures control over any Improvement, MPP shall request such Sublicensee or any of their employee, agent or other person (each, an “Improvement Creator”) to communicate such Improvement to MEDIGEN in full together with all available information concerning the mode of working and using the same. MEDIGEN shall treat this information as Confidential Information;
FORM OF SUBLICENCE AGREEMENT
9. INTELLECTUAL PROPERTY RIGHTS
9.1 MEDIGEN will own the entire right, title and interest in and to any and all inventions conceived solely by MEDIGEN (or its Affiliates) or on its behalf, by its respective employees and agents after the Effective Date relating to the Product in the Field, including any adaptation of any manufacturing process or proprietary drug delivery or formulation technology of MEDIGEN or its Affiliates for the production of the Product in the Field, and any patents covering such invention (“MEDIGEN New Developments”), subject to the license grant to the Sublicensee set out in Clause 2 hereof. MPP shall notify Sublicensee in writing of any MEDIGEN New Developments as soon as it receives relevant information from MEDIGEN pursuant to the MEDIGEN-MPP Agreement.